In June 2003, the PCPT was stopped early because of a clear finding that finasteride reduced the incidence of prostate cancer. However, those trial participants who did develop prostate cancer while taking finasteride experienced a slightly higher incidence of high-grade tumors. Researchers analyzing the data have shown that because men taking finasteride have a reduced prostate size, this contributes to finding more high-grade tumors on biopsy. Additionally, researchers also found that high-grade cancer was detected earlier and in a less extensive stage in the finasteride group than in the placebo group.
Prostate cancer is a critical public health problem: more than 220,000 men will be diagnosed with prostate cancer in the United States this year and almost 29,000 will die of the disease.
There is strong evidence that physical activity is associated with reduced risk of cancers of the colon and breast.
Several studies have also reported links between physical activity and reduced risk of endometrial (lining of the uterus), lung, and prostate cancers.